ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed the Russell 1000 Value Index in the first quarter. On an absolute basis, the strategy has gained 9 out of eleven sectors it invested in during the quarter. Financial and utilities sectors were the leading contributors while the real estate and healthcare sectors detracted. Overall stock selection and sector allocation contributed to returns relatively. In addition, please check the fund’s top five holdings to know its best picks in 2024. ClearBridge Value Equity Strategy highlighted stocks like Biogen Inc. (NASDAQ:BIIB), in the first quarter 2024 investor letter. Biogen Inc. (NASDAQ:BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The one-month return of Biogen Inc. (NASDAQ:BIIB) was -2.23%, and its shares lost 19.80% of their value over the last 52 weeks. On July 1, 2024, Biogen Inc. (NASDAQ:BIIB) stock closed at $231.77 per share with a market capitalization of $33.317 billion. ClearBridge Value Equity Strategy stated the following regarding Biogen Inc. (NASDAQ:BIIB) in its first quarter 2024 investor letter: "Several of our health care companies also faced idiosyncratic challenges during the quarter. For example, Biogen Inc. (NASDAQ:BIIB), a biotechnology company developing treatments for Alzheimer’s and other neurological disorders, came under pressure after reporting lower than expected revenue growth for the fourth quarter due to weaker than expected sales from its multiple sclerosis and spinal muscular atrophy drugs. However, we believe these challenges are transitory and see room for improvement through its rollout of new products and management’s cost-cutting initiatives." A patient receiving physical therapy for a neurological disease. Biogen Inc. (NASDAQ:BIIB) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held Biogen Inc. (NASDAQ:BIIB) at the end of the first quarter which was 51 in the previous quarter. The total revenue of Biogen Inc. (NASDAQ:BIIB) in the first quarter was $2.3 billion, representing a decrease of 7% in actual and constant currency. While we acknowledge the potential of Biogen Inc. (NASDAQ:BIIB) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We discussed Biogen Inc. (NASDAQ:BIIB) in another article and shared Morgan Stanley’s top stock picks for 2024. Patient Capital Opportunity Equity Strategy added Biogen Inc. (NASDAQ:BIIB) to its portfolio in Q1 2024. In addition, please check out our hedge fund investor letters Q1 2024 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...